Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 461 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Type 2 Diabetics Clear all

Conditions: Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer Due to Type 1 Diabetes Mellitus, Diabetic Foot Ulcer
Interventions: XWRAP; Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Diabetes Mellitus: Type 1
Interventions: Technosphere Insulin® Inhalation Powder, RAA Population; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Chula Vista, California • San Antonio, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more

Conditions: Diabetes Mellitus, Type 2
Interventions: rosiglitazone/metformin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 49
States / cities: Anniston, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions: SB-509, Placebo; Drug
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: La Jolla, California • Walnut Creek, California • Houston, Texas + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: muraglitazar; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 108
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more

Conditions: Hypertension
Interventions: olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more

Conditions: Type 2 Diabetes
Interventions: Januvia (Sitagliptin) 100 mg, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 20 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773 placebo, BI 10773 low dose, BI 10773 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: Fasiglifam, Placebo, Antihyperglycemic therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1292263, GSK1292263 matching placebo, Sitagliptin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more

Conditions: Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Ruboxistaurin mesylate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 19
States / cities: Mesa, Arizona • Irvine, California • Los Angeles, California + 16 more

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: Renal Autologous Cell Therapy (REACT); Biological
Lead sponsor: Prokidney; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Tucson, Arizona • Boise, Idaho • Chapel Hill, North Carolina + 1 more

Conditions: Diabetic Ulcers
Interventions: Vasculera; Dietary Supplement
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 25 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes
Interventions: Colesevelam, Placebo, Diet, Metformin; Drug · Other · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide (1 Mg Dose), Placebo; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Linagliptin, Linagliptin Placebo, Glimepiride; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 15
States / cities: Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more

Conditions: Type 2 Diabetes Mellitus With Diabetic Nephropathy
Interventions: IW-1973, Placebo; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 54
States / cities: Birmingham, Alabama • Chula Vista, California • Fullerton, California + 42 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Low Metformin, Metformin, Mid Metformin, High Metformin; Drug
Lead sponsor: NuSirt Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more

Conditions: Type 2 Diabetes
Interventions: Cocoa polyphenols; Dietary Supplement
Lead sponsor: Arpita Basu; Other
Eligibility: 21 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Stillwater, Oklahoma

Conditions: Prediabetes / Type 2 Diabetes
Interventions: Whey Protein Isolate Crossover, Placebo; Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 50 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: At-risk Drinking, Type 2 Diabetes
Interventions: Brief alcohol intervention, General health education; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetic Foot, Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown
Interventions: Real Time Continuous Glucose Monitoring (rt-CGM), Fingerstick blood glucose (FBG) monitoring, Diabetes Education; Device · Other · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Obesity, Morbid, Diabetes Mellitus, Type 2, Gastric Bypass
Interventions: Not listed
Lead sponsor: CPL Associates; Other
Eligibility: 18 Years to 95 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Buffalo, New York • Williamsville, New York

Search by objective public record fields.

A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

Treatment of GLP-1 for Diabetic Bariatric Patients

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes

Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals

Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics

CGM and DFU Healing Post-discharge

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics